rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MGX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Metagenomi at Jefferies Global Healthcare Conference: hemophilia bet advances
      10h agoInvesting.comMGXJEF
      Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London

      EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in London, UK, on Wednesday, November 18, 2026, at 12:00 p.

      Nov 11Yahoo FinanceMGX
      Metagenomi Therapeutics: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceMGX
      FDA clears Metagenomi’s hemophilia A gene therapy trial
      Nov 10Investing.comMGX
      Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
      Nov 10Yahoo FinanceMGX
      Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
      Nov 4Yahoo FinanceMGX
      Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference

      EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a panel discussion titled “Genome Editing: Next-Wave Platforms Beyond CRISPR 1.0” at the Chardan 10th Annual Healthcare Conference on

      Oct 13Yahoo FinanceCRSPMGX
      Metagenomi director Laurence Reid buys $23,401 in company stock
      Sep 12Investing.comMGX
      Metagenomi general counsel Matthew Wein sells $414 in stock
      Sep 10Investing.comMGX
      Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock
      Sep 10Investing.comMGX
      Metagenomi at Wells Fargo conference: hemophilia program advances
      Sep 10Investing.comMGXWFC
      Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
      Sep 1BarchartMGX

      This is the newest page. Registered accounts read further back.